Pliant: Positive Safety, Efficacy Data in Phase 2a Trial in Sclerosing Cholangitis, Liver Fibrosis

 

• Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts
• Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12
• The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings
• Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET

The Company will host a conference call and webcast with a slide presentation tomorrow, Monday, February 5, 2024, at 8:00 a.m. ET | 5:00 a.m. PT to discuss this update. Members of Pliant’s management team will be joined by Gideon Hirshfield, FRCP, Ph.D., Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto. Interested parties may access the live webcast on Pliant’s website at Pliant Therapeutics INTEGRIS-PSC Webcast or may participate via telephone by registering in advance at the following link: Pliant Therapeutics INTEGRIS-PSC Conference Call. Upon registration, all telephone participants will receive the dial-in number along and a unique passcode to access the call. An archived replay of the webcast will be available on Pliant’s website for 60 days following completion of the event.

https://www.biospace.com/article/releases/pliant-therapeutics-announces-positive-safety-and-exploratory-efficacy-data-from-the-integris-psc-phase-2a-trial-of-bexotegrast-320-mg-in-patients-with-primary-sclerosing-cholangitis-and-suspected-liver-fibrosis/